Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer: What Schedule and Duration of Treatment?

European Urology

Volumn 52, Issue 4, 2007, Pages 951-953

  Sylvester, Richard J ^a  

^a European Organisation of Research and Treatment of Cancer   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN C;

BCG VACCINATION; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; DYSURIA; EDITORIAL; FOLLOW UP; HEMATURIA; HUMAN; LONG TERM CARE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 34548316294     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.028     Document Type: Editorial

References (10)

1. Lamm D.L., Riggs D.R., Traynelis C.L., and Nseyo O.U. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
2. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces the recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
3. Sylvester R.J., Oosterlinck W., and van der Meijden A.P.M. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
4. Au J.L.S., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
5. Tolley D.A., Parmar M.K.B., Grigor K.M., and Lallemand G. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: further report with 7 years of followup. J Urol 155 (1996) 1233-1238
6. Koga H., Kuroiwa K., Yamaguchi A., Osada Y., Tsuneyoshi M., and Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 171 (2004) 153-157
7. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153 (1995) 934-941
8. Ali-el-Dein B., Nabeeh A., El-Baz M., Shamaa S., and Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79 (1997) 731-735
9. Schwaibold H., Pichlmeier U., Klingenberger H.J., and Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Eur Urol 31 (1997) 153-159
10. Kuroda M., Niijima T., Kotake T., Akaza H., and Hinotsu S. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-the 6th trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45 (2004) 600-605